Thesis (Ph. D.)--University of Adelaide, Dept. of Crop Protection, 1998. / Includes bibliographical references (leaves 134-151).

Thesis (Ph.D.) -- University of Adelaide, Dept. of Plant Pathology, 1983. / Typescript (photocopy).

Thesis--Syracuse University. / Vita. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (leaves [1-25] (3d group)).

Thesis--Syracuse University. / Vita. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (leaves [1-25] (3d group)).

No description available.

Thesis (Ph. D.) -- Lincoln University, 2009. / Also available via the World Wide Web.

abstract: The majority of chronic myeloid leukemia (CML) and some of acute lymphocytic leukemia (ALL) cases are associated with possessing the BCR-Abl fusion protein from an oncogenic translocation, resulting in a constantly active form of Abl and rapid proliferation. CML and ALL cells that possess the BCR-Abl fusion protein are known as Philadelphia chromosome positive (Ph+). Currently, Imatinib (selective Abl inhibitor) is used as therapy against CML and ALL. However, some patients may have malignancies which show resistance to Imatinib. Previous work displays that the transformation of progenitor B cells with the v-Abl oncogene of Abelson murine leukemia virus results in cell cycle progression, rapid proliferation, and potentially malignant transformation while preventing any further differentiation. Progenitor B cells transformed with the temperature-sensitive form of the v-Abl oncogene have served as a model to study cellular response to Imatinib treatment. After some manipulation, very few cells were forced to progress to malignancy, forming tumor in vivo. These cells were no long sensitive to v-Abl inactivation, resembling the Imatinib resistant ALL. Autophagy is the process by which proteins and organelles are broken-down and recycled within the eukaryotic cell and has been hypothesized to play a part in cancer cell survival and drug-resistance. LC3 processing is a widely accepted marker of autophagy induction and progression. It has also been shown that Imatinib treatment of Ph+ leukemia can induce autophagy. In this study, we examined the autophagy induction in response to v-Abl inactivation in a Ph+-B-ALL cell model that shows resistance to Imatinib. In particular, we wonder whether the tumor cell line resistant to v-Abl inactivation may acquire a high level of autophagy to become resistant to apoptosis induced by v-Abl inactivation, and thus become addicted to autophagy. Indeed, this tumor cell line displays a high basal levels of LC3 I and II expression, regardless of v-Abl activity. We further demonstrated that inhibition of the autophagy pathway enhances the tumor line's sensitivity to Imatinib, resulting in cell cycle arrest and massive apoptosis. The combination of autophagy and Abl inhibitions may serve as an effective therapy for BCR-Abl positive CML. / Dissertation/Thesis / M.S. Biological Design 2011

Submitted by Pós Imunologia (ppgimicsufba@gmail.com) on 2017-02-07T19:17:53Z No. of bitstreams: 1 Tese_KM_final.pdf: 2714851 bytes, checksum: ae197797f7e0966b1ad54595314ce1fa (MD5) / Approved for entry into archive by Delba Rosa (delba@ufba.br) on 2017-02-08T16:21:02Z (GMT) No. of bitstreams: 1 Tese_KM_final.pdf: 2714851 bytes, checksum: ae197797f7e0966b1ad54595314ce1fa (MD5) / Made available in DSpace on 2017-02-08T16:21:02Z (GMT). No. of bitstreams: 1 Tese_KM_final.pdf: 2714851 bytes, checksum: ae197797f7e0966b1ad54595314ce1fa (MD5) / CAPES / O tratamento das leucemias agudas continua sendo um grande desafio clínico devido, principalmente à heterogeneidade e alta toxicidade da terapia padrão utilizada. Dessa forma, novos alvos terapêuticos são urgentemente necessários e os anticorpos monoclonais tem surgido como uma das opções terapêuticas mais promissoras. A endoglina, também conhecida como CD105, é um receptor da superfamília do TGF-β, expresso nas células-tronco hematopoiéticas (HSC) de todos os sítios hematopoiéticos, incluindo a medula óssea, onde é descrita como um marcador para HSC de longo prazo. Apesar da expressão de CD105 ter sido relacionada a diversos tipos de tumores sólidos, principalmente devido ao papel desse receptor na angiogênese, relativamente pouco é conhecido em relação a expressão de CD105 e a sua função em neoplasias hematopoiéticas. Este estudo revelou alta expressão de endoglin na maioria dos blastos de pacientes com leucemia mieloide aguda (LMA) e leucemia linfoblástica aguda (LLA). Utilizando um modelo de xenotransplante, verificamos que as blastos CD105+ possuem uma actividade leucemogênica superior em comparação com a população de CD105-. Adicionalmente, investigamos se o bloqueio da endoglina, usando TRC105, poderia resultar em uma opção terapêutica para tratamento das leucemias agudas e descobrimos que na LMA, o TRC105 impediu o engraftment de blastos primários e inibiu a progressão da leucemia após o estabelecimento da doença, mas na LLA, o TRC105 sozinho foi ineficaz devido à uma maior secreção da forma soluvél da endoglina (sENG). No entanto, tanto na LLA quanto na LMA, TRC105 potencializou o efeito terapeutico da quimioterapia padrão e inibiu a progressão da doença, indicando que TRC105 pode representar uma nova opção terapêutica para LLA e LMA. / Successful treatment of acute leukemia remains a clinical challenge due to the toxicity and the relatively poor responses to the current standard therapy. Thus, treatments that address novel therapeutic targets are urgently needed and, for this purpose, monoclonal antibodies have been one of the most promising strategy once they are able to deliver their therapeutic effects with minimal toxicity. Endoglin, also known as CD105, is a receptor of the transforming growth factor-beta (TGF-β) superfamily that has been found expressed in hematopoietic stem cells (HSCs) from all hematopoietic sites, including the bone marrow, in which it is described as a marker for long-term HSC. CD105 is also found to be expressed in several cancers. However, because CD105 expression has been studied mostly in the context of solid tumors and angiogenesis, relatively little is known about CD105 expression and role in hematopoietic malignancies. We identified endoglin expression on the majority of blasts from patients with acute myeloid leukemia (AML) and acute B-lymphoblastic leukemia (B-ALL). Using a xenograft model, we find that CD105+ blasts are endowed with superior leukemogenic activity compared to the CD105- population. We test the effect of targeting this receptor using the monoclonal antibody TRC105, and find that in AML, TRC105 prevented the engraftment of primary AML blasts and inhibited leukemia progression following disease establishment, but in B-ALL, TRC105 alone was ineffective due to the shedding of soluble CD105. However, in both B-ALL and AML, TRC105 synergized with reduced intensity myeloablation to inhibit leukemogenesis, indicating that TRC105 may represent a novel therapeutic option for B-ALL and AML.

This dissertation presents searches for direct pair production of a scalar partner of the top quark in events with only jets and \acrlong{met} in proton--proton collisions recorded during LHC Run 1 and Run 2 with the ATLAS detector. In the supersymmetry scenario, the partner is called top squark or stop. The stop ($\stop$) is assumed to decay via $\stop \to t \ninoone$, $\stop\to b\chinoonepm \to b W^{\left(\ast\right)} \ninoone$, or $\stop\ra bW\ninoone$, where $\ninoone$ ($\chinoonepm$) denotes the lightest neutralino (chargino). Exclusion limits are reported in terms of the stop and neutralino masses. The LHC Run 1 analysis uses an integrated luminosity of 20.1~{\ifb} at $\acrshort{sqrts}=8~\tev$ to exclude top squark masses in the range $270$--$645~\GeV$ for $\ninoone$ masses below $30~\GeV$, assuming a 100\% $\stop \to t \ninoone$ \gls{br}. For a \gls{br} of $50\%$ to either $\stop \to t \ninoone$ or $\stop\to b\chinoonepm$, and assuming $m_{\chinoonepm} = 2 m_{\ninoone}$, stop masses in the range $250$--$550~\GeV$ are excluded for $\ninoone$ masses below $60~\GeV$. The LHC Run 2 analysis uses an integrated luminosity of 13.3~{\ifb} at $\acrshort{sqrts}=13~\tev$. Assuming a 100\% $\stop \to t \ninoone$ \gls{br}, stop masses in the range $310$--$820~\GeV$ are excluded for $\ninoone$ masses below $160~\GeV$. For $\mstop\sim m_t+\mLSP$ scenario, the search excludes stop masses between $23$--$380~\GeV$. Additionally, scenarios where stops are produced indirectly through gluino decay but have very low $p_T$ signature due to a very small $\Delta (\mstop, \mLSP)$, have been considered. The result is interpreted as an upper limit for the cross section in terms of the gluino and stop masses. This excludes all models considered which include $m_{\gluino}$ up to 1600~\GeV\ with $\mLSP<560~\GeV$ at 95\% CL. Finally, the analysis strategy from the LHC Run 1 search is applied in the broader scope of supersymmetry called \gls{pmssm}. This dissertation presents a summary of the results that related to the stop search.

Bakgrund: Akut lymfatisk leukemi (ALL) är den vanligaste cancerformen bland barn och ungdomar och kan innebära stor fysisk och psykisk påfrestning hos föräldrar och barn. När barnet drabbas av ALL kan föräldrar känna oro och rädsla för att förlora barnet. Syfte: Syftet med studien var att belysa föräldrars upplevelser när barnet har drabbats av akut lymfatisk leukemi (ALL). Metod: En litteraturstudie med induktiv ansats genomfördes där elva artiklar granskades och valdes till resultat. Resultat: I resultatet framkom huvudkategorin: Upplevelse av att vara förälder till barn som drabbats av ALL med underkategorier: att känna livet krascha, att känna otillräcklighet, att oroas över ekonomin, att känna behov av förändrade föräldrastrategier och att blicka framåt. Andra huvudkategorin var Upplevelse av sjuksköterskans betydelse med underkategorier: att känna emotionellt stöd och att uppleva behov av information och undervisning. Föräldrar upplevde kommunikation med sjuksköterska som viktigt och hjälpte föräldrar hantera påfrestningen. Vid bristande kommunikation upplevde föräldrar att sjuksköterskan undanhöll information och tilliten till sjuksköterskan försvann. Slutsats: Studien kan ge kunskap om föräldrars upplevelser när barnet drabbas av ALL och vilka behov som finns av hjälp och stöd. Mer forskning krävs för att undersöka på vilket sätt sjuksköterskan kan underlätta för föräldrar under den påfrestande tiden. / Background: Acute lymphocytic leukemia (ALL) is the most common cancer in children and youth and may cause great physical and psychological burden on parents and children. Parents might worry and fear losing the child when their child has ALL. Aim: The aim of this study was to explore parent's experiences when their child suffered from acute lymphocytic leukemia (ALL). Method: A literature review with an inductive structure was performed where eleven articles were analyzed and chosen for results. Result: The result presents main category: Experience of being a parent off a child affected by ALL with subcategories: to feel life crashing, to feel insufficient, to worry about economics, to feel the need of changing parent strategies, to focus ahead. The second main category was The experience of the importance of the nurse with subcategories: to feel emotional support and to experience the need for information and education. Parents experienced that communication with the nurse was important and helped parents manage burden. Lack of communication made parents experience that the nurse withheld information and the trust disappeared. Conclusions: The study can provide knowledge about parent's experiences when their child has ALL and the need of help and support. More research is required to investigate in which way the nurse can ease parent's burden during the stressful time.